Posted from: Tuesday, September 05, 2017 - 04:29 PM - Present

Second Biosimilar for Remicade Launched

July 24, 2017 – Merck and Samsung Bioepis have released Renflexis™ (infliximab-abda) in the United States. The launch comes three months after the drug was granted U.S. FDA approval on April 21, 2017. A tumor necrosis factor (TNF) inhibitor, Renflexis is a biosimilar for Janssen Biotech’s Remicade® (infliximab). It is indicated for the treatment of ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis (RA), Crohn’s disease in both adults and children, and ulcerative colitis.

Dosing recommendations for Renflexis vary by indication. Like other infliximab drugs, it includes a medication guide and black box warning that it may cause lymphomas or other cancers among children and teens, as well as serious infections in patients of any age.

Renflexis is the second biosimilar to Remicade to be launched in the U.S. The first, Pfizer and Celltrion‘s Inflectra® (infliximab-dyyb), entered the market in November of 2016. The anticipated list price for Renflexis is $750 per 100mg vial, which is approximately $420 less per vial than Remicade, and $200 less than Inflectra. Johnson & Johnson, Janssen’s parent company, reports that 2016 U.S. sales of Remicade totaled approximately $5 billion.

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by U.S. mail or by fax.

Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.

 

Last Updated Wednesday, September 20, 2017 - 01:13 AM.